@DerErdnussmann@OVI_USA@PaultheGrandppa “Real revenue, global expansion, survival” — true. But funded by constant dilution, margins still negative, and price targets backed by vibes, not models. The script is the same as 2021, just with different catalysts. Surviving ≠ thriving. $TLRY
@DerErdnussmann@OVI_USA@PaultheGrandppa I’m not insulting, just saying what I being listen since 2021, put this in your head, you can catch some dead cat bounce but if you want to see real move, CEO and board needs to change
@Politiksuechtig I’ll tell you, that $ is from shares dilutions, made by the bad CEO and board that this company has, if you’re willing to just give away your $, you can but you’ll be dumb, and don’t trust nothing @IrwinDSimon says he hasn’t deliver nothing to shareholders, only he’s pocket grows
@OVI_USA@VinodSeetharag1@TLRY_Happy@tilray@TilrayIR “Listen” You are buying 💩 company with shareholders money, without delivering what you praise, it’s not a direct consequences of environment, if there where consequences the just the CEO wouldn’t take home 10.000.000$ or more.
@tlry = losing money in the next 10 years
@OVI_USA You’re arguing potential, not certainty. Regulatory shifts don’t fix dilution or weak execution at Tilray, sector tailwinds ≠ company performance.
How much?
@OVI_USA You’re confusing narrative with fundamentals. The Drug Enforcement Administration process may move sentiment, but it doesn’t fix weak margins, dilution, or lack of profitability, that can drive volatility - not a structural revaluation.
How much do they pay you?